Enhertu improved PFS in mBC in DESTINY-Breast02
15 August 2022 07:00 BST Enhertu significantly delayed disease progression in DESTINY-Breast02Phase III trial vs. physician's choice of treatment in patients with HER2-positive metastatic breast cancer Results consistent with previous trials, reinforcing benefit of AstraZeneca and Daiichi Sankyo's Enhertu in previously treated patients Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician's choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically